Our genome-wide CRISPR knockout screen during imlunestrant treatment showed that known vulnerabilities in HR+ breast cancer, such as genes related to the CDK4/6-RB1 axis and PI3Kinase signaling pathway, remain essential in the presence of imlunestrant treatment. Here, RB1 is linked to breast carcinoma.